Skip to main navigation Skip to search Skip to main content

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

  • Lecia V. Sequist
  • , Ji Youn Han
  • , Myung Ju Ahn
  • , Byoung Chul Cho
  • , Helena Yu
  • , Sang We Kim
  • , James Chih Hsin Yang
  • , Jong Seok Lee
  • , Wu Chou Su
  • , Dariusz Kowalski
  • , Sergey Orlov
  • , Mireille Cantarini
  • , Remy B. Verheijen
  • , Anders Mellemgaard
  • , Lone Ottesen
  • , Paul Frewer
  • , Xiaoling Ou
  • , Geoffrey Oxnard
  • Massachusetts General Hospital
  • National Cancer Center
  • Yonsei University
  • Memorial Sloan-Kettering Cancer Center
  • University of Ulsan
  • National Taiwan University
  • Seoul National University
  • National Cheng Kung University
  • Maria Sklodowska-Curie Institute of Oncology
  • BioEq, LLC
  • AstraZeneca
  • Dana-Farber Cancer Institute

Research output: Contribution to journal › Article › peer-review

406   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study'. Together they form a unique fingerprint.
Sort by

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology